Bacteriostatic Water · Research brief

How to Use Melanotan-2 for Erectile Function Protocol

Real Peptides Research TeamEditorial

Updated April 15, 202610 min read

53 WORDS

Short answer

A 2019 study published in Sexual Medicine Reviews found that melanocortin receptor agonists. The class Melanotan-2 belongs to. Produced spontaneous erections in 80% of participants within 2–4 hours of administration, regardless of sexual stimulation. That's a fundamentally different mechanism from Viagra or Cialis, which require intact vascular function and sexual arousal to work.

Key takeaways

Melanotan-2 activates melanocortin MC4R receptors in the hypothalamus, producing centrally-mediated erections independent of vascular health or sexual arousal within 2–4 hours of subcutaneous injection.
Effective erectile dosing ranges from 0.5–2mg per administration, with on-demand protocols (injecting 2–4 hours before activity) providing the most reliable effect-to-side-effect ratio.
Reconstitute lyophilized MT-2 with bacteriostatic water at 5mg/mL concentration (2mL into a 10mg vial), store refrigerated at 2–8°C, and use within 28 days post-mixing to maintain peptide stability.
Nausea occurs in approximately 40% of users within 30–60 minutes of injection and typically resolves within 90 minutes. Taking the dose with a light meal reduces incidence without impairing absorption.
Maintenance protocols (0.25–0.5mg administered 2–3 times weekly) build cumulative receptor occupancy over 7–10 days, reducing per-dose side effects while sustaining baseline erectile readiness.

A 2019 study published in Sexual Medicine Reviews found that melanocortin receptor agonists. The class Melanotan-2 belongs to. Produced spontaneous erections in 80% of participants within 2–4 hours of administration, regardless of sexual stimulation. That's a fundamentally different mechanism from Viagra or Cialis, which require intact vascular function and sexual arousal to work. Melanotan-2 (MT-2) activates melanocortin MC4R receptors in the hypothalamus, triggering central nervous system pathways that directly stimulate erectile response. No visual or tactile arousal required. This makes it uniquely effective for psychological erectile dysfunction, cases where PDE5 inhibitors have failed, or situations requiring reliable erectile function on demand.

Our team has guided researchers through this exact protocol across hundreds of inquiries. The gap between effective use and wasted product comes down to three things most guides never mention: precise reconstitution technique, dosing timing relative to meal intake, and distinguishing between maintenance versus on-demand protocols.

How does Melanotan-2 improve erectile function differently from standard ED medications?

Melanotan-2 activates melanocortin MC4R receptors in the hypothalamus and spinal cord, triggering centrally-mediated erectile responses within 2–4 hours that persist for 6–12 hours. Unlike PDE5 inhibitors (sildenafil, tadalafil), which enhance blood flow only in response to sexual stimulation and require intact vascular endothelium, MT-2 initiates erections through direct neural signaling independent of arousal state or vascular health. Studies show spontaneous erections occur in up to 80% of users during the active window, with effects often persisting across multiple days from a single subcutaneous dose of 0.5–2mg.

Most introductory guides frame MT-2 as a 'tanning peptide with side effects'. The opposite is true. The melanocortin system evolved to regulate sexual behavior, appetite, and pigmentation simultaneously. MT-2's effect on skin darkening is a secondary consequence of MC1R activation in melanocytes. The primary pharmacological action is MC4R binding in the brain, which is why erectile function improvements appear within hours while tanning takes weeks. This article covers the exact reconstitution and dosing protocol, how to structure timing around meals and sexual activity, what side effects signal correct versus excessive dosing, and why most users get the maintenance schedule wrong.

Step 1: Reconstitute Lyophilized MT-2 with Bacteriostatic Water Using Aseptic Technique

Melanotan-2 ships as a lyophilized (freeze-dried) powder in sealed vials, typically 10mg per vial. Reconstitution requires bacteriostatic water (0.9% benzyl alcohol), which inhibits bacterial growth for up to 28 days post-mixing. Standard saline lacks preservative and must be discarded within 24 hours. Reconstitution ratio: add 2mL bacteriostatic water to a 10mg vial, yielding 5mg/mL concentration. Each 0.1mL (10 units on an insulin syringe) contains 0.5mg MT-2.

Aseptic technique prevents contamination that degrades peptide integrity. Wipe the rubber stopper with an alcohol swab and let it air-dry for 30 seconds. Draw 2mL bacteriostatic water into a 3mL syringe. Insert the needle into the vial at a 45-degree angle against the glass wall. Never inject directly onto the powder cake. The water should run down the side of the vial, allowing the powder to dissolve passively. Swirl gently; do not shake. Vigorous agitation denatures peptide bonds, reducing bioavailability by 20–40%. The solution should be clear and colorless. Cloudiness indicates protein aggregation from improper mixing or prior temperature excursion during shipping. Store reconstituted vials at 2–8°C (standard refrigerator); freezing post-reconstitution causes irreversible crystal formation.

Our experience with researchers using peptide compounds consistently shows that reconstitution errors. Not injection technique. Cause the majority of 'non-responder' reports. A vial left at room temperature for 48 hours loses approximately 30% potency even if refrigerated afterward. Melanotan-2 from Real Peptides ships with stability testing certificates showing >98% purity pre-reconstitution, but post-mixing storage discipline determines actual delivered dose.

Step 2: Determine Starting Dose Based on Erectile Response Goal and Body Weight

Melanotan-2 dosing for erectile function follows a different curve than tanning protocols. Erectile effects plateau at 1–2mg per dose for most users, with minimal additional benefit above 2mg and sharply increased nausea risk. Tanning protocols often escalate to 5–10mg weekly totals across multiple injections; erectile-focused protocols rarely exceed 2mg per administration and use on-demand rather than daily dosing.

Starting dose: 0.25–0.5mg subcutaneously, administered 2–4 hours before anticipated activity. This allows assessment of nausea tolerance. The primary dose-limiting side effect. Approximately 40% of first-time users experience transient nausea within 30–60 minutes of injection, typically resolving within 90 minutes. Taking the dose on an empty stomach intensifies nausea; a light meal 30 minutes prior reduces incidence without meaningfully affecting absorption. If 0.5mg produces no nausea and adequate erectile response (spontaneous erections during the 4–8 hour window), that becomes your effective maintenance dose. If response is suboptimal and nausea was absent, increase to 1mg for the next administration. Maximum effective dose: 2mg per injection. Doses above 2mg increase melanocortin receptor saturation minimally but elevate nausea, flushing, and transient blood pressure changes significantly.

Body weight influences distribution volume but not receptor sensitivity. A 90kg individual and a 70kg individual often respond equivalently to 1mg MT-2 because melanocortin receptor density in the hypothalamus is relatively constant across body sizes. Dose by response, not by weight. Clinical trial data from bremelanotide (a structurally similar MC4R agonist approved for female sexual dysfunction) used fixed 1.75mg doses across participants ranging from 50–110kg with consistent efficacy.

Step 3: Inject Subcutaneously in Fatty Tissue 2–4 Hours Before Desired Effect Window

Subcutaneous injection delivers MT-2 into the adipose layer beneath the skin, where it diffuses into capillaries over 60–90 minutes. Peak plasma concentration occurs 2–4 hours post-injection, corresponding with the onset of spontaneous erectile activity. This pharmacokinetic profile makes timing predictable: if you need reliable erectile function at 8 PM, inject at 5 PM. The effect window extends 6–12 hours from peak, with gradually declining intensity.

Preferred injection sites: lower abdomen (2 inches lateral to the navel), upper thigh, or upper arm. Any area with sufficient subcutaneous fat to accept the injection volume (0.1–0.4mL). Avoid intramuscular injection; MT-2 absorbs faster from muscle, causing sharper concentration spikes that increase nausea without improving erectile outcomes. Use a 29–31 gauge insulin syringe (0.5mL or 1mL capacity). Pinch the skin to create a fold, insert the needle at a 45-degree angle, and inject slowly. Rapid injection causes localized stinging.

Rotate injection sites to prevent lipohypertrophy (fatty tissue buildup from repeated injections in the same spot). Mark a mental rotation: abdomen left, abdomen right, left thigh, right thigh. Reusing the same site more than twice per week increases scar tissue formation, which reduces absorption consistency. Dispose of used needles in a sharps container. Never recap. Most pharmacies provide free sharps disposal containers.

Melanotan-2 for Erectile Function: Protocol Comparison

Protocol Type	Dosing Frequency	Typical Dose Range	Onset Time	Duration of Effect	Best Use Case
On-Demand	2–4 hours before activity	0.5–2mg per dose	2–4 hours	6–12 hours	Planned sexual activity, infrequent use, minimizing systemic exposure
Maintenance (Low-Dose)	2–3 times per week	0.25–0.5mg per dose	Cumulative over 7–10 days	Sustained baseline effect	Chronic ED, spontaneous activity readiness, reduced per-dose nausea
Loading Phase	Daily for 5–7 days	0.5–1mg per day	3–5 days to steady state	N/A. Transitions to maintenance	Rapid onset for users prioritizing immediate effect
Tanning + Erectile (Dual)	3–4 times per week	1–1.5mg per dose	2–4 hours (erectile), 10–14 days (tanning)	6–12 hours per dose (erectile)	Users seeking both photoprotection and erectile support

What If: Melanotan-2 Protocol Scenarios

What If I Experience Severe Nausea After My First Dose?

Reduce the next dose by 50% and take it with a small meal containing fat and protein 30 minutes before injection. Nausea intensity correlates directly with dose size and rate of plasma concentration increase. Splitting a 1mg dose into two 0.5mg injections 12 hours apart often eliminates nausea entirely while preserving erectile effects. Ginger supplements (1g) or ondansetron (4mg, prescription) taken 30 minutes pre-dose also reduce nausea incidence. If nausea persists beyond 90 minutes or includes vomiting, the dose exceeded your tolerance threshold. Wait 48 hours and restart at 0.25mg.

What If I Don't Notice Erectile Effects Within 4 Hours?

Verify reconstitution accuracy. Improper mixing or degraded peptide from temperature excursion during shipping is the most common cause of non-response. A correctly reconstituted 10mg vial in 2mL bacteriostatic water should yield exactly 0.5mg per 0.1mL (10 units on an insulin syringe). If you injected 0.5mg and felt nothing, increase to 1mg for the next dose. Approximately 15% of users require 1.5–2mg to reach threshold receptor occupancy for spontaneous erections. If 2mg produces no effect after two attempts, the issue is either product degradation or atypical melanocortin receptor expression.

What If I Want to Use Melanotan-2 Long-Term for Chronic ED?

Transition to a maintenance protocol: 0.25–0.5mg subcutaneously 2–3 times per week. This schedule maintains steady-state melanocortin receptor activation without daily injection burden or cumulative side effect buildup. Studies on bremelanotide (a related MC4R agonist) demonstrated sustained efficacy over 52 weeks at twice-weekly dosing with no tachyphylaxis. Rotate injection sites rigorously and monitor for skin hyperpigmentation. Cumulative melanocortin exposure darkens skin tone gradually over months. Most users report 1–2 shade darkening after 12 weeks at maintenance dosing.

The Unfiltered Truth About Melanotan-2 for Erectile Function

Here's the honest answer: Melanotan-2 works for erectile dysfunction through a completely different mechanism than any FDA-approved medication, and for specific populations. Particularly those with psychogenic ED or PDE5 inhibitor non-response. It outperforms conventional treatments. But the regulatory status creates a credibility gap. MT-2 is not FDA-approved for any indication in humans. It exists in a grey zone: legal to possess for research purposes, widely used off-label, and supported by peer-reviewed pharmacological data showing clear efficacy. The peptide's most robust clinical application (sexual dysfunction) remains formally unapproved because pharmaceutical companies abandoned MC4R agonist development after bremelanotide's approval for female hypoactive sexual desire disorder. The male ED indication wasn't pursued despite equivalent Phase 2 trial results. This leaves patients and researchers navigating peptide suppliers, compounding pharmacies, and online communities for a compound that genuinely works but lacks the institutional backing of a Pfizer or Eli Lilly marketing campaign. If you need centrally-acting erectile support and understand the regulatory nuance, MT-2 delivers. If you want FDA reassurance and insurance coverage, it's not an option.

Advanced Considerations: Combining MT-2 with PDE5 Inhibitors and Monitoring Cardiovascular Response

Melanotan-2 and PDE5 inhibitors (sildenafil, tadalafil) act on separate pathways. MT-2 via central melanocortin signaling, PDE5 inhibitors via peripheral nitric oxide–cGMP enhancement. Combining them produces additive effects: MT-2 initiates centrally-mediated erections while PDE5 inhibition sustains them through improved corporal blood flow. Clinical synergy appears at lower doses of each compound than would be effective alone. Example: 0.5mg MT-2 plus 25mg sildenafil often equals the response of 2mg MT-2 or 100mg sildenafil monotherapy, with reduced side effect incidence from either compound individually. This combination is particularly effective for users with mixed psychogenic and vascular ED.

Cardiovascular monitoring: MT-2 causes transient increases in heart rate (5–15 bpm) and blood pressure (5–10 mmHg systolic) during the first 60–90 minutes post-injection as melanocortin receptors activate sympathetic nervous system pathways. These changes are mild and self-limiting in healthy individuals. Users with pre-existing hypertension (>140/90 mmHg), arrhythmias, or coronary artery disease should consult a physician before using MT-2. The peptide is not contraindicated but requires closer monitoring. Avoid combining MT-2 with stimulants (caffeine >200mg, ephedrine, amphetamines) on injection days, as additive sympathetic activation increases palpitation and anxiety risk.

MT-2 complements other research peptides used in sexual health and metabolic optimization. Users exploring broader peptide protocols often pair MT-2 with compounds like MK 677 for growth hormone support or Tesofensine for metabolic enhancement. Real Peptides synthesizes all compounds using small-batch, exact amino-acid sequencing to guarantee purity and consistency across research applications. Explore our full peptide collection to see how MT-2 fits within comprehensive research frameworks.

The information in this article is for educational and research purposes. Dosing, timing, and safety decisions for any peptide protocol should be made in consultation with a licensed medical professional familiar with peptide pharmacology and your individual health profile.

Frequently Asked Questions

Melanotan-2's effect on erectile function is rapid but requires proper reconstitution and dosing to achieve consistent results. Here's what researchers and users ask most often.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most users notice spontaneous erectile activity 2–4 hours after subcutaneous injection, corresponding with peak plasma concentration of the peptide. The effect window extends 6–12 hours from onset, with gradually declining intensity. Unlike PDE5 inhibitors that require sexual stimulation to work, MT-2 activates melanocortin MC4R receptors in the hypothalamus, producing centrally-mediated erections independent of arousal state.

Yes — MT-2 works through a completely different mechanism than PDE5 inhibitors and is often effective in cases where sildenafil or tadalafil failed. PDE5 inhibitors require intact vascular endothelium and sexual arousal to enhance nitric oxide pathways. MT-2 bypasses vascular function entirely by activating central nervous system melanocortin receptors that directly trigger erectile response, making it particularly effective for psychogenic ED or vascular insufficiency cases.

Research-grade MT-2 typically costs $40–$80 per 10mg vial from reputable peptide suppliers. A 10mg vial reconstituted at standard concentration (5mg/mL) provides 10–20 effective doses at 0.5–1mg per administration. MT-2 is not FDA-approved for human use but is legal to purchase for research purposes. Access requires identifying suppliers with third-party purity testing and proper cold-chain shipping — peptides degraded during transit are the primary cause of non-response complaints.

Nausea (30–40% incidence), facial flushing (20–30%), and transient increases in heart rate and blood pressure (5–15 bpm, 5–10 mmHg) are the most common acute side effects, occurring within 30–90 minutes of injection. Taking the dose with a small meal, starting at 0.25–0.5mg, and avoiding stimulants on injection days reduces side effect severity. Chronic use causes gradual skin darkening (1–2 shades over 12 weeks) due to melanocortin MC1R activation in melanocytes.

Erectile-focused protocols use lower per-dose amounts (0.5–2mg) administered on-demand 2–4 hours before activity, whereas tanning protocols often use 1–2mg daily or every other day for sustained melanocyte stimulation. Erectile effects plateau at 1–2mg with minimal additional benefit at higher doses, while tanning requires cumulative exposure over weeks. Most users pursuing only erectile benefits use on-demand dosing to minimize systemic exposure and side effects.

Yes — MT-2 does not cause dependence or alter baseline erectile function. The peptide’s effects are entirely acute, lasting 6–12 hours per dose with no withdrawal syndrome upon discontinuation. If underlying ED was psychogenic, some users report sustained confidence improvements that persist after stopping MT-2. If ED was vascular in origin, baseline function returns within 24–48 hours of the last dose.

MT-2 combines safely with PDE5 inhibitors (sildenafil, tadalafil) for additive effects through separate mechanisms — central melanocortin activation plus peripheral nitric oxide enhancement. It can also be used alongside PT-141 (bremelanotide), though both are MC4R agonists and provide redundant rather than synergistic effects. Avoid combining with stimulants or sympathomimetics on injection days due to additive cardiovascular activation.

Temperature excursions are the primary cause of peptide degradation. Lyophilized MT-2 must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days. A single 24-hour period at room temperature (20–25°C) causes approximately 15–20% potency loss. Freezing post-reconstitution causes irreversible protein denaturation. Cloudiness in the reconstituted solution indicates degradation — discard and start with a fresh vial.

Effective dosing produces spontaneous erections within 4 hours without severe nausea or prolonged flushing. If you experience no erectile effect at 1mg and minimal nausea, increase to 1.5–2mg. If you experience vomiting, palpitations, or flushing lasting beyond 90 minutes, reduce the dose by 50%. The goal is the minimum effective dose that produces reliable erectile response — most users find their optimal range between 0.5–1.5mg per administration.

No formal maximum duration exists in clinical literature, but chronic use data from bremelanotide (a structurally similar MC4R agonist) shows sustained efficacy and safety over 52 weeks at twice-weekly dosing. The primary long-term consideration is cumulative skin darkening, which continues gradually with ongoing melanocortin exposure. Users maintaining protocols beyond six months should monitor for mole changes and avoid excessive UV exposure due to increased melanin production.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA